+357 96 030922
info@marketpublishers.com

Global Investigational New Drug CDMO Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/G5D6BF4F1ACBEN.html
Date: November 2026
Pages: 172
Price: US$ 4,480.00 (Single User License)
ID: G5D6BF4F1ACBEN

Abstracts

The global Investigational New Drug CDMO market size is expected to reach $ 37070 million by 2032, rising at a market growth of 8.9% CAGR during the forecast period (2026-2032).

Investigational New Drug CDMO services comprise outsourced CMC development and GMP manufacturing that convert a preclinical drug candidate into clinical-trial-ready drug substance and drug product and then supply Phase I–III studies. The scope includes process, formulation and analytical development, method validation, stability, IND/IMPD-supporting documentation, GMP clinical batches, aseptic or oral drug-product manufacture, packaging and integrated clinical supply when connected to development/manufacturing. It covers small molecules, biologics, peptides, oligonucleotides, ADCs and advanced therapies.

Key Findings

Integrated pre-IND-to-clinic platforms reduce technology transfers

Emerging biotech demand favors flexible small-batch capacity

Complex modalities raise analytical and aseptic manufacturing value

Market Trends

Sponsors increasingly select CDMOs before IND-enabling studies so process, analytical, formulation and manufacturing decisions are made with later clinical scale in

+357 96 030922
info@marketpublishers.com

mind. Platform development, standardized cell-line or chemistry packages and integrated drug-substance/drug-product execution shorten handoffs. Demand is also moving toward high-potency, sterile, biologic and advanced-therapy capabilities, where analytical characterization, regulatory documentation and supply-chain resilience determine timelines more than nominal reactor capacity.

Market Dynamics

Drivers

A growing biotech pipeline, constrained internal CMC teams and pressure to reach first-in-human dosing accelerate outsourcing. Complex modalities and global trials increase demand for specialized GMP facilities and integrated supply.

Restraints

Funding cycles can delay or cancel early programs, while technology transfer, minimum campaign size and scarce specialist capacity increase switching costs. Sponsors may retain strategic processes internally.

Opportunities

DNA-to-IND, candidate-to-clinic and one-site drug-substance/drug-product offerings can compress timelines. Flexible suites, continuous manufacturing, high-potency containment, prefilled syringes and regional dual sourcing create differentiated growth.

Challenges

CDMOs must manage immature processes, changing forecasts and phase-appropriate controls without compromising data integrity. Regulatory observations, contamination, batch failure or late analytical gaps can stop a trial and damage multi-client capacity schedules.

Industry Chain Analysis

+357 96 030922
info@marketpublishers.com

Upstream resources include starting materials, excipients, single-use bioprocess components, cell lines, plasmids, media, chromatography resins, vials, stoppers, analytical instruments and cold-chain inputs. CDMOs integrate developability assessment, process and formulation design, analytical methods, scale-up, GMP drug-substance and drug-product batches, release, stability and regulatory CMC packages. Clinical supply teams add packaging, randomization labels, storage and distribution, while sponsors and clinical sites administer the investigational product. Value concentrates in scientific problem solving, validated quality systems, regulatory-ready data, flexible GMP capacity and on-time clinical release; simple material procurement carries lower margin.

Segment Insights

Small molecules remain the largest modality by project count and benefit from broad chemistry, API and oral-dose infrastructure. Monoclonal antibodies and recombinant proteins command larger campaign values and increasingly use standardized cell-line-to-IND platforms. Peptides, oligonucleotides and ADCs require specialized synthesis, conjugation and high-containment analytics. Cell and gene therapies have smaller project counts but high service intensity because vector production, potency assays, aseptic handling and chain-of-identity controls are complex.

Downstream Market Opportunities

Pre-IND and Phase I programs offer the largest customer-acquisition opportunity because emerging biotech sponsors need rapid process definition, tox and GMP material, regulatory CMC support and first clinical supply. Phase II creates repeat campaigns, formulation optimization and scale-up work. Phase III and registration-enabling programs deliver larger revenue but demand validated processes, redundancy and inspection readiness. Integrated providers can retain programs across stages; specialists win where potency, modality or dosage-form complexity outweighs one-stop convenience.

Regional Insights

North America is the largest source of emerging-biotech projects and a major center for sterile, biologic and advanced-therapy outsourcing. Europe combines mature API, biologics and fill-finish clusters with strict IMPD and Qualified Person release practices. China has developed a broad preclinical-to-clinical CDMO base led by companies

+357 96 030922
info@marketpublishers.com

including WuXi AppTec, STA Pharmaceutical, Asymchem Laboratories (Tianjin) Co., Ltd., Porton Pharma Solutions Ltd., Pharmaron Beijing Co., Ltd., Zhejiang Jiuzhou Pharmaceutical Co., Ltd., MabPlex International, DINGKANG BIO and GenScript ProBio. Japan and South Korea are expanding biologics capacity, while sponsors increasingly qualify regional backups to manage geopolitical and logistics risk.

Competitive Landscape Analysis

Verified representative providers include Thermo Fisher Scientific Patheon, Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Boehringer Ingelheim BioXcellence, Rentschler Biopharma, Siegfried, Cambrex, CordenPharma, Curia, Piramal Pharma Solutions, Recipharm, PCI Pharma Services, Almac Group, Ajinomoto Bio-Pharma Services, Vetter, WuXi AppTec, STA Pharmaceutical, Asymchem Laboratories (Tianjin) Co., Ltd., Porton Pharma Solutions Ltd., Pharmaron Beijing Co., Ltd., Zhejiang Jiuzhou Pharmaceutical Co., Ltd., MabPlex International, DINGKANG BIO and GenScript ProBio. Global scale players compete on integrated modality breadth and network capacity; specialists compete on speed, scientific depth and flexible batches. Inclusion reflects official service evidence, not an audited revenue ranking.

Report Scope

This report studies the global Investigational New Drug CDMO demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Investigational New Drug CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Investigational New Drug CDMO that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Investigational New Drug CDMO total market, 2021-2032, (USD Million)

Global Investigational New Drug CDMO total market by region & country,

+357 96 030922
info@marketpublishers.com

CAGR, 2021-2032, (USD Million)

U.S. VS China: Investigational New Drug CDMO total market, key domestic companies, and share, (USD Million)

Global Investigational New Drug CDMO revenue by player, revenue and market share 2021-2026, (USD Million)

Global Investigational New Drug CDMO total market by Type, CAGR, 2021-2032, (USD Million)

Global Investigational New Drug CDMO total market by End User, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Investigational New Drug CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher Scientific Patheon, Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Boehringer Ingelheim BioXcellence, Rentschler Biopharma, Siegfried, Cambrex, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Investigational New Drug CDMO market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by End User. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Investigational New Drug CDMO Market, By Region:

+357 96 030922
info@marketpublishers.com

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Investigational New Drug CDMO Market, Segmentation by Type:

Small Molecules

Monoclonal Antibodies and Recombinant Proteins

Peptides and Oligonucleotides

Cell and Gene Therapies

ADCs and Other Complex Modalities

Global Investigational New Drug CDMO Market, Segmentation by Clinical Phase:

Pre-IND and Phase I

+357 96 030922
info@marketpublishers.com

Phase II

Phase III and Registration-enabling

Global Investigational New Drug CDMO Market, Segmentation by Service Stage:

Preformulation and CMC Development

Process and Analytical Development

GMP Clinical Drug-substance Manufacturing

Clinical Drug-product Manufacturing

Packaging, Labeling and Clinical Supply

Global Investigational New Drug CDMO Market, Segmentation by End User:

Biotech Companies

Pharma Companies

Academic and Virtual Biotech

Companies Profiled:

Thermo Fisher Scientific Patheon

Lonza

Catalent

Samsung Biologics

+357 96 030922
info@marketpublishers.com

FUJIFILM Diosynth Biotechnologies

AGC Biologics

Boehringer Ingelheim BioXcellence

Rentschler Biopharma

Siegfried

Cambrex

CordenPharma

Curia

Piramal Pharma Solutions

Recipharm

PCI Pharma Services

Almac Group

Ajinomoto Bio-Pharma Services

Vetter

WuXi AppTec

STA Pharmaceutical

Asymchem Laboratories (Tianjin) Co., Ltd.

Porton Pharma Solutions Ltd.

Pharmaron Beijing Co., Ltd.

+357 96 030922
info@marketpublishers.com

Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

MabPlex International

DINGKANG BIO

GenScript ProBio

Key Questions Answered

1. How big is the global Investigational New Drug CDMO market?
2. What is the demand of the global Investigational New Drug CDMO market?
3. What is the year over year growth of the global Investigational New Drug CDMO market?
4. What is the total value of the global Investigational New Drug CDMO market?
5. Who are the Major Players in the global Investigational New Drug CDMO market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Investigational New Drug CDMO Introduction
1.2 World Investigational New Drug CDMO Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Investigational New Drug CDMO Total Market by Region (by Headquarter Location)
  1.3.1 World Investigational New Drug CDMO Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Investigational New Drug CDMO Revenue (2021-2032)
  1.3.3 China Based Company Investigational New Drug CDMO Revenue (2021-2032)
  1.3.4 Europe Based Company Investigational New Drug CDMO Revenue (2021-2032)
  1.3.5 Japan Based Company Investigational New Drug CDMO Revenue (2021-2032)
  1.3.6 South Korea Based Company Investigational New Drug CDMO Revenue (2021-2032)
  1.3.7 ASEAN Based Company Investigational New Drug CDMO Revenue (2021-2032)
  1.3.8 India Based Company Investigational New Drug CDMO Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Investigational New Drug CDMO Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Investigational New Drug CDMO Consumption Value (2021-2032)
2.2 World Investigational New Drug CDMO Consumption Value by Region
  2.2.1 World Investigational New Drug CDMO Consumption Value by Region (2021-2026)
  2.2.2 World Investigational New Drug CDMO Consumption Value Forecast by Region (2027-2032)
2.3 United States Investigational New Drug CDMO Consumption Value (2021-2032)
2.4 China Investigational New Drug CDMO Consumption Value (2021-2032)
2.5 Europe Investigational New Drug CDMO Consumption Value (2021-2032)
2.6 Japan Investigational New Drug CDMO Consumption Value (2021-2032)
2.7 South Korea Investigational New Drug CDMO Consumption Value (2021-2032)
2.8 ASEAN Investigational New Drug CDMO Consumption Value (2021-2032)

+357 96 030922
info@marketpublishers.com

2.9 India Investigational New Drug CDMO Consumption Value (2021-2032)

3 WORLD INVESTIGATIONAL NEW DRUG CDMO COMPANIES COMPETITIVE ANALYSIS

3.1 World Investigational New Drug CDMO Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global Investigational New Drug CDMO Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for Investigational New Drug CDMO in 2025
  3.2.3 Global Concentration Ratios (CR8) for Investigational New Drug CDMO in 2025
3.3 Investigational New Drug CDMO Company Evaluation Quadrant
3.4 Investigational New Drug CDMO Market: Overall Company Footprint Analysis
  3.4.1 Investigational New Drug CDMO Market: Region Footprint
  3.4.2 Investigational New Drug CDMO Market: Company Product Type Footprint
  3.4.3 Investigational New Drug CDMO Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Investigational New Drug CDMO Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: Investigational New Drug CDMO Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
  4.1.2 United States VS China: Investigational New Drug CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Investigational New Drug CDMO Consumption Value Comparison
  4.2.1 United States VS China: Investigational New Drug CDMO Consumption Value Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: Investigational New Drug CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Investigational New Drug CDMO Companies and Market Share, 2021-2026
  4.3.1 United States Based Investigational New Drug CDMO Companies, Headquarters

+357 96 030922
info@marketpublishers.com

(States, Country)
4.3.2 United States Based Companies Investigational New Drug CDMO Revenue, (2021-2026)
4.4 China Based Companies Investigational New Drug CDMO Revenue and Market Share, 2021-2026
4.4.1 China Based Investigational New Drug CDMO Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Investigational New Drug CDMO Revenue, (2021-2026)
4.5 Rest of World Based Investigational New Drug CDMO Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Investigational New Drug CDMO Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Investigational New Drug CDMO Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Investigational New Drug CDMO Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Small Molecules
5.2.2 Monoclonal Antibodies and Recombinant Proteins
5.2.3 Peptides and Oligonucleotides
5.2.4 Cell and Gene Therapies
5.2.5 ADCs and Other Complex Modalities
5.3 Market Segment by Type
5.3.1 World Investigational New Drug CDMO Market Size by Type (2021-2026)
5.3.2 World Investigational New Drug CDMO Market Size by Type (2027-2032)
5.3.3 World Investigational New Drug CDMO Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY CLINICAL PHASE

6.1 World Investigational New Drug CDMO Market Size Overview by Clinical Phase: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Clinical Phase
6.2.1 Pre-IND and Phase I
6.2.2 Phase II

+357 96 030922
info@marketpublishers.com

6.2.3 Phase III and Registration-enabling
6.3 Market Segment by Clinical Phase
6.3.1 World Investigational New Drug CDMO Market Size by Clinical Phase (2021-2026)
6.3.2 World Investigational New Drug CDMO Market Size by Clinical Phase (2027-2032)
6.3.3 World Investigational New Drug CDMO Market Size Market Share by Clinical Phase (2027-2032)

7 MARKET ANALYSIS BY SERVICE STAGE

7.1 World Investigational New Drug CDMO Market Size Overview by Service Stage: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Service Stage
7.2.1 Preformulation and CMC Development
7.2.2 Process and Analytical Development
7.2.3 GMP Clinical Drug-substance Manufacturing
7.2.4 Clinical Drug-product Manufacturing
7.2.5 Packaging, Labeling and Clinical Supply
7.3 Market Segment by Service Stage
7.3.1 World Investigational New Drug CDMO Market Size by Service Stage (2021-2026)
7.3.2 World Investigational New Drug CDMO Market Size by Service Stage (2027-2032)
7.3.3 World Investigational New Drug CDMO Market Size Market Share by Service Stage (2027-2032)

8 MARKET ANALYSIS BY END USER

8.1 World Investigational New Drug CDMO Market Size Overview by End User: 2021 VS 2025 VS 2032
8.2 Segment Introduction by End User
8.2.1 Biotech Companies
8.2.2 Pharma Companies
8.2.3 Academic and Virtual Biotech
8.3 Market Segment by End User
8.3.1 World Investigational New Drug CDMO Market Size by End User (2021-2026)
8.3.2 World Investigational New Drug CDMO Market Size by End User (2027-2032)
8.3.3 World Investigational New Drug CDMO Market Size Market Share by End User

+357 96 030922
info@marketpublishers.com

(2021-2032)

9 COMPANY PROFILES

9.1 Thermo Fisher Scientific Patheon
  9.1.1 Thermo Fisher Scientific Patheon Details
  9.1.2 Thermo Fisher Scientific Patheon Major Business
  9.1.3 Thermo Fisher Scientific Patheon Investigational New Drug CDMO Product and Services
  9.1.4 Thermo Fisher Scientific Patheon Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
  9.1.5 Thermo Fisher Scientific Patheon Recent Developments/Updates
  9.1.6 Thermo Fisher Scientific Patheon Competitive Strengths & Weaknesses
9.2 Lonza
  9.2.1 Lonza Details
  9.2.2 Lonza Major Business
  9.2.3 Lonza Investigational New Drug CDMO Product and Services
  9.2.4 Lonza Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
  9.2.5 Lonza Recent Developments/Updates
  9.2.6 Lonza Competitive Strengths & Weaknesses
9.3 Catalent
  9.3.1 Catalent Details
  9.3.2 Catalent Major Business
  9.3.3 Catalent Investigational New Drug CDMO Product and Services
  9.3.4 Catalent Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
  9.3.5 Catalent Recent Developments/Updates
  9.3.6 Catalent Competitive Strengths & Weaknesses
9.4 Samsung Biologics
  9.4.1 Samsung Biologics Details
  9.4.2 Samsung Biologics Major Business
  9.4.3 Samsung Biologics Investigational New Drug CDMO Product and Services
  9.4.4 Samsung Biologics Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
  9.4.5 Samsung Biologics Recent Developments/Updates
  9.4.6 Samsung Biologics Competitive Strengths & Weaknesses
9.5 FUJIFILM Diosynth Biotechnologies
  9.5.1 FUJIFILM Diosynth Biotechnologies Details

+357 96 030922
info@marketpublishers.com

9.5.2 FUJIFILM Diosynth Biotechnologies Major Business
9.5.3 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Product and Services
9.5.4 FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
9.5.6 FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
9.6 AGC Biologics
9.6.1 AGC Biologics Details
9.6.2 AGC Biologics Major Business
9.6.3 AGC Biologics Investigational New Drug CDMO Product and Services
9.6.4 AGC Biologics Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 AGC Biologics Recent Developments/Updates
9.6.6 AGC Biologics Competitive Strengths & Weaknesses
9.7 Boehringer Ingelheim BioXcellence
9.7.1 Boehringer Ingelheim BioXcellence Details
9.7.2 Boehringer Ingelheim BioXcellence Major Business
9.7.3 Boehringer Ingelheim BioXcellence Investigational New Drug CDMO Product and Services
9.7.4 Boehringer Ingelheim BioXcellence Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Boehringer Ingelheim BioXcellence Recent Developments/Updates
9.7.6 Boehringer Ingelheim BioXcellence Competitive Strengths & Weaknesses
9.8 Rentschler Biopharma
9.8.1 Rentschler Biopharma Details
9.8.2 Rentschler Biopharma Major Business
9.8.3 Rentschler Biopharma Investigational New Drug CDMO Product and Services
9.8.4 Rentschler Biopharma Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Rentschler Biopharma Recent Developments/Updates
9.8.6 Rentschler Biopharma Competitive Strengths & Weaknesses
9.9 Siegfried
9.9.1 Siegfried Details
9.9.2 Siegfried Major Business
9.9.3 Siegfried Investigational New Drug CDMO Product and Services
9.9.4 Siegfried Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Siegfried Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

9.9.6 Siegfried Competitive Strengths & Weaknesses
9.10 Cambrex
9.10.1 Cambrex Details
9.10.2 Cambrex Major Business
9.10.3 Cambrex Investigational New Drug CDMO Product and Services
9.10.4 Cambrex Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Cambrex Recent Developments/Updates
9.10.6 Cambrex Competitive Strengths & Weaknesses
9.11 CordenPharma
9.11.1 CordenPharma Details
9.11.2 CordenPharma Major Business
9.11.3 CordenPharma Investigational New Drug CDMO Product and Services
9.11.4 CordenPharma Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 CordenPharma Recent Developments/Updates
9.11.6 CordenPharma Competitive Strengths & Weaknesses
9.12 Curia
9.12.1 Curia Details
9.12.2 Curia Major Business
9.12.3 Curia Investigational New Drug CDMO Product and Services
9.12.4 Curia Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Curia Recent Developments/Updates
9.12.6 Curia Competitive Strengths & Weaknesses
9.13 Piramal Pharma Solutions
9.13.1 Piramal Pharma Solutions Details
9.13.2 Piramal Pharma Solutions Major Business
9.13.3 Piramal Pharma Solutions Investigational New Drug CDMO Product and Services
9.13.4 Piramal Pharma Solutions Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Piramal Pharma Solutions Recent Developments/Updates
9.13.6 Piramal Pharma Solutions Competitive Strengths & Weaknesses
9.14 Recipharm
9.14.1 Recipharm Details
9.14.2 Recipharm Major Business
9.14.3 Recipharm Investigational New Drug CDMO Product and Services
9.14.4 Recipharm Investigational New Drug CDMO Revenue, Gross Margin and

+357 96 030922
info@marketpublishers.com

Market Share (2021-2026)
9.14.5 Recipharm Recent Developments/Updates
9.14.6 Recipharm Competitive Strengths & Weaknesses
9.15 PCI Pharma Services
9.15.1 PCI Pharma Services Details
9.15.2 PCI Pharma Services Major Business
9.15.3 PCI Pharma Services Investigational New Drug CDMO Product and Services
9.15.4 PCI Pharma Services Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 PCI Pharma Services Recent Developments/Updates
9.15.6 PCI Pharma Services Competitive Strengths & Weaknesses
9.16 Almac Group
9.16.1 Almac Group Details
9.16.2 Almac Group Major Business
9.16.3 Almac Group Investigational New Drug CDMO Product and Services
9.16.4 Almac Group Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Almac Group Recent Developments/Updates
9.16.6 Almac Group Competitive Strengths & Weaknesses
9.17 Ajinomoto Bio-Pharma Services
9.17.1 Ajinomoto Bio-Pharma Services Details
9.17.2 Ajinomoto Bio-Pharma Services Major Business
9.17.3 Ajinomoto Bio-Pharma Services Investigational New Drug CDMO Product and Services
9.17.4 Ajinomoto Bio-Pharma Services Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Ajinomoto Bio-Pharma Services Recent Developments/Updates
9.17.6 Ajinomoto Bio-Pharma Services Competitive Strengths & Weaknesses
9.18 Vetter
9.18.1 Vetter Details
9.18.2 Vetter Major Business
9.18.3 Vetter Investigational New Drug CDMO Product and Services
9.18.4 Vetter Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Vetter Recent Developments/Updates
9.18.6 Vetter Competitive Strengths & Weaknesses
9.19 WuXi AppTec
9.19.1 WuXi AppTec Details
9.19.2 WuXi AppTec Major Business

+357 96 030922
info@marketpublishers.com

9.19.3 WuXi AppTec Investigational New Drug CDMO Product and Services
9.19.4 WuXi AppTec Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 WuXi AppTec Recent Developments/Updates
9.19.6 WuXi AppTec Competitive Strengths & Weaknesses
9.20 STA Pharmaceutical
9.20.1 STA Pharmaceutical Details
9.20.2 STA Pharmaceutical Major Business
9.20.3 STA Pharmaceutical Investigational New Drug CDMO Product and Services
9.20.4 STA Pharmaceutical Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 STA Pharmaceutical Recent Developments/Updates
9.20.6 STA Pharmaceutical Competitive Strengths & Weaknesses
9.21 Asymchem Laboratories (Tianjin) Co., Ltd.
9.21.1 Asymchem Laboratories (Tianjin) Co., Ltd. Details
9.21.2 Asymchem Laboratories (Tianjin) Co., Ltd. Major Business
9.21.3 Asymchem Laboratories (Tianjin) Co., Ltd. Investigational New Drug CDMO Product and Services
9.21.4 Asymchem Laboratories (Tianjin) Co., Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments/Updates
9.21.6 Asymchem Laboratories (Tianjin) Co., Ltd. Competitive Strengths & Weaknesses
9.22 Porton Pharma Solutions Ltd.
9.22.1 Porton Pharma Solutions Ltd. Details
9.22.2 Porton Pharma Solutions Ltd. Major Business
9.22.3 Porton Pharma Solutions Ltd. Investigational New Drug CDMO Product and Services
9.22.4 Porton Pharma Solutions Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Porton Pharma Solutions Ltd. Recent Developments/Updates
9.22.6 Porton Pharma Solutions Ltd. Competitive Strengths & Weaknesses
9.23 Pharmaron Beijing Co., Ltd.
9.23.1 Pharmaron Beijing Co., Ltd. Details
9.23.2 Pharmaron Beijing Co., Ltd. Major Business
9.23.3 Pharmaron Beijing Co., Ltd. Investigational New Drug CDMO Product and Services
9.23.4 Pharmaron Beijing Co., Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

9.23.5 Pharmaron Beijing Co., Ltd. Recent Developments/Updates
9.23.6 Pharmaron Beijing Co., Ltd. Competitive Strengths & Weaknesses
9.24 Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
9.24.1 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Details
9.24.2 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Major Business
9.24.3 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Investigational New Drug CDMO Product and Services
9.24.4 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Recent Developments/Updates
9.24.6 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.25 MabPlex International
9.25.1 MabPlex International Details
9.25.2 MabPlex International Major Business
9.25.3 MabPlex International Investigational New Drug CDMO Product and Services
9.25.4 MabPlex International Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 MabPlex International Recent Developments/Updates
9.25.6 MabPlex International Competitive Strengths & Weaknesses
9.26 DINGKANG BIO
9.26.1 DINGKANG BIO Details
9.26.2 DINGKANG BIO Major Business
9.26.3 DINGKANG BIO Investigational New Drug CDMO Product and Services
9.26.4 DINGKANG BIO Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 DINGKANG BIO Recent Developments/Updates
9.26.6 DINGKANG BIO Competitive Strengths & Weaknesses
9.27 GenScript ProBio
9.27.1 GenScript ProBio Details
9.27.2 GenScript ProBio Major Business
9.27.3 GenScript ProBio Investigational New Drug CDMO Product and Services
9.27.4 GenScript ProBio Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.27.5 GenScript ProBio Recent Developments/Updates
9.27.6 GenScript ProBio Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

+357 96 030922
info@marketpublishers.com

10.1 Investigational New Drug CDMO Industry Chain
10.2 Investigational New Drug CDMO Upstream Analysis
10.3 Investigational New Drug CDMO Midstream Analysis
10.4 Investigational New Drug CDMO Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Investigational New Drug CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Investigational New Drug CDMO Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Investigational New Drug CDMO Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Investigational New Drug CDMO Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Investigational New Drug CDMO Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Investigational New Drug CDMO Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Investigational New Drug CDMO Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Investigational New Drug CDMO Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Investigational New Drug CDMO Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Investigational New Drug CDMO Players in 2025
Table 12. World Investigational New Drug CDMO Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Investigational New Drug CDMO Company Evaluation Quadrant
Table 14. Head Office of Key Investigational New Drug CDMO Players
Table 15. Investigational New Drug CDMO Market: Company Product Type Footprint
Table 16. Investigational New Drug CDMO Market: Company Product Application Footprint
Table 17. Investigational New Drug CDMO Mergers & Acquisitions Activity
Table 18. United States VS China Investigational New Drug CDMO Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Investigational New Drug CDMO Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Investigational New Drug CDMO Companies, Headquarters (States, Country)

+357 96 030922
info@marketpublishers.com

Table 21. United States Based Companies Investigational New Drug CDMO Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Investigational New Drug CDMO Revenue Market Share (2021-2026)
Table 23. China Based Investigational New Drug CDMO Companies, Headquarters (Province, Country)
Table 24. China Based Companies Investigational New Drug CDMO Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Investigational New Drug CDMO Revenue Market Share (2021-2026)
Table 26. Rest of World Based Investigational New Drug CDMO Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Investigational New Drug CDMO Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Investigational New Drug CDMO Revenue Market Share (2021-2026)
Table 29. World Investigational New Drug CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Investigational New Drug CDMO Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Investigational New Drug CDMO Market Size by Type (2027-2032) & (USD Million)
Table 32. World Investigational New Drug CDMO Market Size by Clinical Phase, (USD Million), 2021 & 2025 & 2032
Table 33. World Investigational New Drug CDMO Market Size Value by Clinical Phase (2021-2026) & (USD Million)
Table 34. World Investigational New Drug CDMO Market Size by Clinical Phase (2027-2032) & (USD Million)
Table 35. World Investigational New Drug CDMO Market Size by Service Stage, (USD Million), 2021 & 2025 & 2032
Table 36. World Investigational New Drug CDMO Market Size Value by Service Stage (2021-2026) & (USD Million)
Table 37. World Investigational New Drug CDMO Market Size by Service Stage (2027-2032) & (USD Million)
Table 38. World Investigational New Drug CDMO Market Size by End User, (USD Million), 2021 & 2025 & 2032
Table 39. World Investigational New Drug CDMO Market Size by End User (2021-2026) & (USD Million)
Table 40. World Investigational New Drug CDMO Market Size by End User (2027-2032)

+357 96 030922
info@marketpublishers.com

& (USD Million)
Table 41. Thermo Fisher Scientific Patheon Basic Information, Manufacturing Base and Competitors
Table 42. Thermo Fisher Scientific Patheon Major Business
Table 43. Thermo Fisher Scientific Patheon Investigational New Drug CDMO Product and Services
Table 44. Thermo Fisher Scientific Patheon Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Thermo Fisher Scientific Patheon Recent Developments/Updates
Table 46. Thermo Fisher Scientific Patheon Competitive Strengths & Weaknesses
Table 47. Lonza Basic Information, Manufacturing Base and Competitors
Table 48. Lonza Major Business
Table 49. Lonza Investigational New Drug CDMO Product and Services
Table 50. Lonza Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Lonza Recent Developments/Updates
Table 52. Lonza Competitive Strengths & Weaknesses
Table 53. Catalent Basic Information, Manufacturing Base and Competitors
Table 54. Catalent Major Business
Table 55. Catalent Investigational New Drug CDMO Product and Services
Table 56. Catalent Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Catalent Recent Developments/Updates
Table 58. Catalent Competitive Strengths & Weaknesses
Table 59. Samsung Biologics Basic Information, Manufacturing Base and Competitors
Table 60. Samsung Biologics Major Business
Table 61. Samsung Biologics Investigational New Drug CDMO Product and Services
Table 62. Samsung Biologics Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Samsung Biologics Recent Developments/Updates
Table 64. Samsung Biologics Competitive Strengths & Weaknesses
Table 65. FUJIFILM Diosynth Biotechnologies Basic Information, Manufacturing Base and Competitors
Table 66. FUJIFILM Diosynth Biotechnologies Major Business
Table 67. FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Product and Services
Table 68. FUJIFILM Diosynth Biotechnologies Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. FUJIFILM Diosynth Biotechnologies Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

Table 70. FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
Table 71. AGC Biologics Basic Information, Manufacturing Base and Competitors
Table 72. AGC Biologics Major Business
Table 73. AGC Biologics Investigational New Drug CDMO Product and Services
Table 74. AGC Biologics Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. AGC Biologics Recent Developments/Updates
Table 76. AGC Biologics Competitive Strengths & Weaknesses
Table 77. Boehringer Ingelheim BioXcellence Basic Information, Manufacturing Base and Competitors
Table 78. Boehringer Ingelheim BioXcellence Major Business
Table 79. Boehringer Ingelheim BioXcellence Investigational New Drug CDMO Product and Services
Table 80. Boehringer Ingelheim BioXcellence Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Boehringer Ingelheim BioXcellence Recent Developments/Updates
Table 82. Boehringer Ingelheim BioXcellence Competitive Strengths & Weaknesses
Table 83. Rentschler Biopharma Basic Information, Manufacturing Base and Competitors
Table 84. Rentschler Biopharma Major Business
Table 85. Rentschler Biopharma Investigational New Drug CDMO Product and Services
Table 86. Rentschler Biopharma Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Rentschler Biopharma Recent Developments/Updates
Table 88. Rentschler Biopharma Competitive Strengths & Weaknesses
Table 89. Siegfried Basic Information, Manufacturing Base and Competitors
Table 90. Siegfried Major Business
Table 91. Siegfried Investigational New Drug CDMO Product and Services
Table 92. Siegfried Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Siegfried Recent Developments/Updates
Table 94. Siegfried Competitive Strengths & Weaknesses
Table 95. Cambrex Basic Information, Manufacturing Base and Competitors
Table 96. Cambrex Major Business
Table 97. Cambrex Investigational New Drug CDMO Product and Services
Table 98. Cambrex Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Cambrex Recent Developments/Updates
Table 100. Cambrex Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

Table 101. CordenPharma Basic Information, Manufacturing Base and Competitors
Table 102. CordenPharma Major Business
Table 103. CordenPharma Investigational New Drug CDMO Product and Services
Table 104. CordenPharma Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. CordenPharma Recent Developments/Updates
Table 106. CordenPharma Competitive Strengths & Weaknesses
Table 107. Curia Basic Information, Manufacturing Base and Competitors
Table 108. Curia Major Business
Table 109. Curia Investigational New Drug CDMO Product and Services
Table 110. Curia Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Curia Recent Developments/Updates
Table 112. Curia Competitive Strengths & Weaknesses
Table 113. Piramal Pharma Solutions Basic Information, Manufacturing Base and Competitors
Table 114. Piramal Pharma Solutions Major Business
Table 115. Piramal Pharma Solutions Investigational New Drug CDMO Product and Services
Table 116. Piramal Pharma Solutions Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Piramal Pharma Solutions Recent Developments/Updates
Table 118. Piramal Pharma Solutions Competitive Strengths & Weaknesses
Table 119. Recipharm Basic Information, Manufacturing Base and Competitors
Table 120. Recipharm Major Business
Table 121. Recipharm Investigational New Drug CDMO Product and Services
Table 122. Recipharm Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Recipharm Recent Developments/Updates
Table 124. Recipharm Competitive Strengths & Weaknesses
Table 125. PCI Pharma Services Basic Information, Manufacturing Base and Competitors
Table 126. PCI Pharma Services Major Business
Table 127. PCI Pharma Services Investigational New Drug CDMO Product and Services
Table 128. PCI Pharma Services Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. PCI Pharma Services Recent Developments/Updates
Table 130. PCI Pharma Services Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

Table 131. Almac Group Basic Information, Manufacturing Base and Competitors
Table 132. Almac Group Major Business
Table 133. Almac Group Investigational New Drug CDMO Product and Services
Table 134. Almac Group Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Almac Group Recent Developments/Updates
Table 136. Almac Group Competitive Strengths & Weaknesses
Table 137. Ajinomoto Bio-Pharma Services Basic Information, Manufacturing Base and Competitors
Table 138. Ajinomoto Bio-Pharma Services Major Business
Table 139. Ajinomoto Bio-Pharma Services Investigational New Drug CDMO Product and Services
Table 140. Ajinomoto Bio-Pharma Services Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Ajinomoto Bio-Pharma Services Recent Developments/Updates
Table 142. Ajinomoto Bio-Pharma Services Competitive Strengths & Weaknesses
Table 143. Vetter Basic Information, Manufacturing Base and Competitors
Table 144. Vetter Major Business
Table 145. Vetter Investigational New Drug CDMO Product and Services
Table 146. Vetter Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Vetter Recent Developments/Updates
Table 148. Vetter Competitive Strengths & Weaknesses
Table 149. WuXi AppTec Basic Information, Manufacturing Base and Competitors
Table 150. WuXi AppTec Major Business
Table 151. WuXi AppTec Investigational New Drug CDMO Product and Services
Table 152. WuXi AppTec Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. WuXi AppTec Recent Developments/Updates
Table 154. WuXi AppTec Competitive Strengths & Weaknesses
Table 155. STA Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 156. STA Pharmaceutical Major Business
Table 157. STA Pharmaceutical Investigational New Drug CDMO Product and Services
Table 158. STA Pharmaceutical Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. STA Pharmaceutical Recent Developments/Updates
Table 160. STA Pharmaceutical Competitive Strengths & Weaknesses
Table 161. Asymchem Laboratories (Tianjin) Co., Ltd. Basic Information, Manufacturing

+357 96 030922
info@marketpublishers.com

Base and Competitors
Table 162. Asymchem Laboratories (Tianjin) Co., Ltd. Major Business
Table 163. Asymchem Laboratories (Tianjin) Co., Ltd. Investigational New Drug CDMO Product and Services
Table 164. Asymchem Laboratories (Tianjin) Co., Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments/Updates
Table 166. Asymchem Laboratories (Tianjin) Co., Ltd. Competitive Strengths & Weaknesses
Table 167. Porton Pharma Solutions Ltd. Basic Information, Manufacturing Base and Competitors
Table 168. Porton Pharma Solutions Ltd. Major Business
Table 169. Porton Pharma Solutions Ltd. Investigational New Drug CDMO Product and Services
Table 170. Porton Pharma Solutions Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Porton Pharma Solutions Ltd. Recent Developments/Updates
Table 172. Porton Pharma Solutions Ltd. Competitive Strengths & Weaknesses
Table 173. Pharmaron Beijing Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 174. Pharmaron Beijing Co., Ltd. Major Business
Table 175. Pharmaron Beijing Co., Ltd. Investigational New Drug CDMO Product and Services
Table 176. Pharmaron Beijing Co., Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Pharmaron Beijing Co., Ltd. Recent Developments/Updates
Table 178. Pharmaron Beijing Co., Ltd. Competitive Strengths & Weaknesses
Table 179. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 180. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Major Business
Table 181. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Investigational New Drug CDMO Product and Services
Table 182. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 184. Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 185. MabPlex International Basic Information, Manufacturing Base and Competitors

+357 96 030922
info@marketpublishers.com

Table 186. MabPlex International Major Business
Table 187. MabPlex International Investigational New Drug CDMO Product and Services
Table 188. MabPlex International Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. MabPlex International Recent Developments/Updates
Table 190. MabPlex International Competitive Strengths & Weaknesses
Table 191. DINGKANG BIO Basic Information, Manufacturing Base and Competitors
Table 192. DINGKANG BIO Major Business
Table 193. DINGKANG BIO Investigational New Drug CDMO Product and Services
Table 194. DINGKANG BIO Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. DINGKANG BIO Recent Developments/Updates
Table 196. DINGKANG BIO Competitive Strengths & Weaknesses
Table 197. GenScript ProBio Basic Information, Manufacturing Base and Competitors
Table 198. GenScript ProBio Major Business
Table 199. GenScript ProBio Investigational New Drug CDMO Product and Services
Table 200. GenScript ProBio Investigational New Drug CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 201. GenScript ProBio Recent Developments/Updates
Table 202. GenScript ProBio Competitive Strengths & Weaknesses
Table 203. Global Key Players of Investigational New Drug CDMO Upstream (Raw Materials)
Table 204. Global Investigational New Drug CDMO Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Investigational New Drug CDMO Picture
Figure 2. World Investigational New Drug CDMO Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Investigational New Drug CDMO Total Revenue (2021-2032) & (USD Million)
Figure 4. World Investigational New Drug CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Investigational New Drug CDMO Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Investigational New Drug CDMO Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Investigational New Drug CDMO Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Investigational New Drug CDMO Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Investigational New Drug CDMO Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Investigational New Drug CDMO Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Investigational New Drug CDMO Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Investigational New Drug CDMO Revenue (2021-2032) & (USD Million)
Figure 13. Investigational New Drug CDMO Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)
Figure 16. World Investigational New Drug CDMO Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)
Figure 18. China Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)

+357 96 030922
info@marketpublishers.com

Figure 20. Japan Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)
Figure 23. India Investigational New Drug CDMO Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Investigational New Drug CDMO by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Investigational New Drug CDMO Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Investigational New Drug CDMO Markets in 2025
Figure 27. United States VS China: Investigational New Drug CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Investigational New Drug CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Investigational New Drug CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Investigational New Drug CDMO Market Size Market Share by Type in 2025
Figure 31. Small Molecules
Figure 32. Monoclonal Antibodies and Recombinant Proteins
Figure 33. Peptides and Oligonucleotides
Figure 34. Cell and Gene Therapies
Figure 35. ADCs and Other Complex Modalities
Figure 36. World Investigational New Drug CDMO Market Size Market Share by Type (2021-2032)
Figure 37. World Investigational New Drug CDMO Market Size by Clinical Phase, (USD Million), 2021 & 2025 & 2032
Figure 38. World Investigational New Drug CDMO Market Size Market Share by Clinical Phase in 2025
Figure 39. Pre-IND and Phase I
Figure 40. Phase II
Figure 41. Phase III and Registration-enabling
Figure 42. World Investigational New Drug CDMO Market Size Market Share by Clinical Phase (2021-2032)
Figure 43. World Investigational New Drug CDMO Market Size by Service Stage, (USD

+357 96 030922
info@marketpublishers.com

Million), 2021 & 2025 & 2032
Figure 44. World Investigational New Drug CDMO Market Size Market Share by Service Stage in 2025
Figure 45. Preformulation and CMC Development
Figure 46. Process and Analytical Development
Figure 47. GMP Clinical Drug-substance Manufacturing
Figure 48. Clinical Drug-product Manufacturing
Figure 49. Packaging, Labeling and Clinical Supply
Figure 50. World Investigational New Drug CDMO Market Size Market Share by Service Stage (2021-2032)
Figure 51. World Investigational New Drug CDMO Market Size by End User, (USD Million), 2021 & 2025 & 2032
Figure 52. World Investigational New Drug CDMO Market Size Market Share by End User in 2025
Figure 53. Biotech Companies
Figure 54. Pharma Companies
Figure 55. Academic and Virtual Biotech
Figure 56. World Investigational New Drug CDMO Market Size Market Share by End User (2021-2032)
Figure 57. Investigational New Drug CDMO Industrial Chain
Figure 58. Methodology
Figure 59. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Investigational New Drug CDMO Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/G5D6BF4F1ACBEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G5D6BF4F1ACBEN.html